CONNECT WITH US
HealthTech

HealthTech

BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer results

Endpoints News logo

Published on

Add as a preferred source on Google
BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer results

BioN­Tech, Du­al­i­ty­Bio pon­der next steps for HER2 ADC af­ter 'mod­est' breast can­cer re­sults

BioN­Tech and Du­al­i­ty­Bio are mulling what to do next with trastuzum­ab pamirte­can in cer­tain breast can­cer pa­tients af­ter the an­ti­body-drug con­ju­gate de­liv­ered a “sta­tis­ti­cal­ly sig­nif­i­cant …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

As­traZeneca's two-pill com­bo may ex­tend Tagris­so's life in lung can­cer October 25, 2026

As­traZeneca eyes Keytru­da's Pad­cev spot; Lil­ly's ADC takes on Ela­here October 24, 2026

Am­gen's Imdell­tra com­bo adds eight months of life in small cell lung can­cer October 24, 2026

Mer­ck and Mod­er­na's can­cer vac­cine da­ta were 'a tri­umph of sci­ence.' And now, the work be­gins

Roche takes vic­to­ry lap with lung can­cer pil­l's win over Am­gen, Bris­tol My­ers

Bris­tol My­ers re­veals death in MS CAR-T tri­al, has an­swer for safe­ty sig­nal in lu­pus tri­al

Swiss biotech Wind­ward Bio files for Nas­daq IPO to fund Chi­na-de­rived as­sets and in-house R&D

Pfiz­er looks be­yond lung can­cer flop as BioN­Tech, Bris­tol My­ers show ear­ly ac­tiv­i­ty



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.